Replimune (REPL)
10.46
-0.29 (2.70%)
Upcoming Events
Latest Headlines
Replimune (REPL) call put ratio 1 call to 1 put amid wide price movement
July 22, 2026 3:57 AM - StreetInsider
Form PRE 14A Replimune Group, Inc. For: Sep 15
July 13, 2026 5:20 PM - SEC Filing
Replimune (REPL) call put ratio 1 call to 1.3 puts with a focus on August options
July 7, 2026 11:08 AM - StreetInsider
BMO Capital Upgrades Replimune Group (REPL) to Outperform
June 30, 2026 4:04 AM - StreetInsider
Form S-8 Replimune Group, Inc.
June 29, 2026 9:18 AM - SEC Filing
Form 10-K Replimune Group, Inc. For: Mar 31
June 29, 2026 8:13 AM - SEC Filing
Form 8-K Replimune Group, Inc. For: Jun 29
June 29, 2026 8:11 AM - SEC Filing
Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update
June 29, 2026 8:00 AM - Globe NewsWire
Replimune (REPL) call put ratio 1.6 calls to 1 put
June 29, 2026 5:56 AM - StreetInsider
JPMorgan Upgrades Replimune Group (REPL) to Overweight
June 26, 2026 12:23 PM - StreetInsider
Increasing unusual put volume: AS WEN REPL BHC BTG IGV HWM CHYM BURL CIA
June 26, 2026 10:32 AM - StreetInsider
Form 8-K Replimune Group, Inc. For: Jun 26
June 26, 2026 8:14 AM - SEC Filing
FDA accepts Replimune RP1 BLA resubmission for advanced melanoma
June 26, 2026 8:01 AM - StreetInsider
Replimune Announces FDA Acceptance of RP1 Biologics License Application Resubmission for Advanced Melanoma
June 26, 2026 8:00 AM - Globe NewsWire
Form 4 Replimune Group, Inc. For: Jun 01 Filed by: Sarchi Christopher
June 3, 2026 8:30 PM - SEC Filing
Replimune (REPL) call put ratio 1 call to 1.2 put amid sharp rally
June 1, 2026 5:42 AM - StreetInsider
Replimune presents final data for RP2 cancer treatment at oncology meeting
June 1, 2026 2:53 AM - StreetInsider
JPMorgan Upgrades Replimune Group (REPL) to Neutral
June 1, 2026 1:06 AM - StreetInsider
Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
May 31, 2026 8:00 AM - Globe NewsWire
Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
May 30, 2026 8:00 AM - StreetInsider
JPMorgan Upgrades Replimune Group (REPL) to Neutral
May 29, 2026 1:15 PM - StreetInsider
Replimune (REPL) call put ratio 1.4 calls to 1 put as share price up 83%
May 29, 2026 10:49 AM - StreetInsider
Form 8-K Replimune Group, Inc. For: May 29
May 29, 2026 9:56 AM - SEC Filing
Replimune plans RP1 cancer drug resubmission after FDA talks
May 29, 2026 8:01 AM - StreetInsider
Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA
May 29, 2026 8:00 AM - Globe NewsWire
Replimune To Resubmit Melanoma Treatment For Fda Approval - WSJ
May 29, 2026 7:33 AM - StreetInsider
Form SCHEDULE 13G Replimune Group, Inc. Filed by: Ridgeback Capital Investments L.P.
May 21, 2026 5:24 PM - SEC Filing
Form 4 Replimune Group, Inc. For: May 18 Filed by: Xynos Konstantinos
May 20, 2026 4:18 PM - SEC Filing
Form 4 Replimune Group, Inc. For: May 18 Filed by: Schwendenman Andrew
May 20, 2026 4:18 PM - SEC Filing
Form 4 Replimune Group, Inc. For: May 18 Filed by: Sarchi Christopher
May 20, 2026 4:17 PM - SEC Filing
Form 4 Replimune Group, Inc. For: May 18 Filed by: Astley-Sparke Philip
May 20, 2026 4:16 PM - SEC Filing
Form 4 Replimune Group, Inc. For: May 18 Filed by: Patel Sushil
May 20, 2026 4:16 PM - SEC Filing
Form 4 Replimune Group, Inc. For: May 18 Filed by: Hill Emily Luisa
May 20, 2026 4:16 PM - SEC Filing
Form SCHEDULE 13G/A Replimune Group, Inc. Filed by: RTW INVESTMENTS, LP
May 15, 2026 8:30 AM - SEC Filing
Form SCHEDULE 13G Replimune Group, Inc. Filed by: SUVRETTA CAPITAL MANAGEMENT, LLC
May 12, 2026 6:32 PM - SEC Filing
FDA Commissioner Marty Makary is resigning - Politico reporter on X
May 12, 2026 12:49 PM - StreetInsider
Replimune shares surge on report Trump to dismiss FDA chief Makary
May 8, 2026 1:32 PM - StreetInsider
Form SCHEDULE 13G/A Replimune Group, Inc. Filed by: PRICE T ROWE ASSOCIATES INC /MD/
May 7, 2026 11:05 AM - SEC Filing
Replimune to Present at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
April 27, 2026 8:00 AM - Globe NewsWire
Full Article List
